What You Should Know
– NVIDIA and Eli Lilly and Company have announced a historic $1B, five-year investment to launch an AI co-innovation lab in the San Francisco Bay Area.
– Utilizing the NVIDIA BioNeMo platform and the next-generation Vera Rubin architecture, the lab will co-locate top AI engineers with biology experts to build a “continuous learning system” that integrates agentic wet labs with robotic manufacturing and physical AI.
The “Continuous Learning” Framework: Connecting Wet and Dry Labs
For decades, the “Valley of Death” in drug discovery has been the gap between computational predictions (dry labs) and experimental validation (wet labs). This collaboration aims to close that gap by creating a 24/7 AI-assisted experimentation loop.
- Scientist-in-the-Loop: Agentic wet labs will generate massive, high-quality datasets that feed directly back into NVIDIA’s foundation models, allowing the AI to “learn” from every physical experiment in real-time.
- BioNeMo as the Backbone: The lab will use NVIDIA BioNeMo™ as the critical platform to accelerate the development of next-generation frontier models for biology and chemistry.
- The Vera Rubin Edge: The initiative intends to harness the NVIDIA Vera Rubin architecture—the most powerful computational framework in the industry—to train models with unprecedented speed and accuracy.
Physical AI and Robotics: Engineering the Supply Chain
The partnership extends beyond the microscope and into the factory. NVIDIA and Lilly are pioneering the use of Physical AI to secure and scale medicine production.
- Digital Twins: Using NVIDIA Omniverse™ and RTX PRO™ Servers, Lilly will create digital twins of its manufacturing lines. This allows engineers to stress-test and optimize supply chains in a virtual environment before implementing physical changes.
- Robotic Manufacturing: The “AI Factory” will utilize robotics to enhance the production capacity of high-demand medications, strengthening supply chain reliability against global disruptions.
“AI is transforming every industry, and its most profound impact will be in life sciences,” said Jensen Huang, founder and CEO of NVIDIA. “NVIDIA and Lilly are bringing together the best of our industries to invent a new blueprint for drug discovery — one where scientists can explore vast biological and chemical spaces in silico before a single molecule is made.”
